AR034921A1 - 2-(3,5-bis-trifluormetil-fenil)-n-[6-(1,1-dioxo-1lambda6-tiomorfolin-4-il)-4-(2-metil o 4-fluor-2-metil substituido)fenil-piridin-3-il]-n-metil-isobutiramida - Google Patents
2-(3,5-bis-trifluormetil-fenil)-n-[6-(1,1-dioxo-1lambda6-tiomorfolin-4-il)-4-(2-metil o 4-fluor-2-metil substituido)fenil-piridin-3-il]-n-metil-isobutiramidaInfo
- Publication number
- AR034921A1 AR034921A1 ARP020102847A ARP020102847A AR034921A1 AR 034921 A1 AR034921 A1 AR 034921A1 AR P020102847 A ARP020102847 A AR P020102847A AR P020102847 A ARP020102847 A AR P020102847A AR 034921 A1 AR034921 A1 AR 034921A1
- Authority
- AR
- Argentina
- Prior art keywords
- phenyl
- 1lambda6
- dioxo
- bis
- disease
- Prior art date
Links
- -1 3,5-BIS-TRIFLUORMETHYL-PHENYL Chemical class 0.000 title abstract 3
- 239000002184 metal Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000019695 Migraine disease Diseases 0.000 abstract 2
- 206010047700 Vomiting Diseases 0.000 abstract 2
- 208000006673 asthma Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 206010027599 migraine Diseases 0.000 abstract 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 abstract 1
- VJYRMMZALMMXPM-UHFFFAOYSA-N 2-[3,5-bis(trifluoromethyl)phenyl]-n-[6-(1,1-dioxo-1,4-thiazinan-4-yl)-4-(2-methylphenyl)pyridin-3-yl]-n,2-dimethylpropanamide Chemical compound C=1N=C(N2CCS(=O)(=O)CC2)C=C(C=2C(=CC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 VJYRMMZALMMXPM-UHFFFAOYSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 1
- 206010066091 Bronchial Hyperreactivity Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010030113 Oedema Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 230000036427 bronchial hyperreactivity Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 231100000040 eye damage Toxicity 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 206010025482 malaise Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 229960002715 nicotine Drugs 0.000 abstract 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 230000009529 traumatic brain injury Effects 0.000 abstract 1
- 230000008673 vomiting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Addiction (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Compuestos 2-(3,5-bis-trifluormetil-fenil)-N-(6-(1,1-dioxo-1lambda6 -tio-morfolin-4-il)-4-o-tolil-piridin-3-il)-N-metil-isobutiramida y 2-(3,5-bis-trifluormetil-fenil)-N-[6-(1,1-dioxo-1lambda6-tiomorfolin-4-il)-4-(4-fluor-2-metil)-piridin-3-il)-N-metil-isobutiramida, que pueden ser de utilidad para el tratamiento de la migrana, artritis reumatoide, asma, hiperreactividad bronquial, enfermedad inflamatoria del intestino o para el tratamiento de trastornos incluyendo la enfermedad de Parkinson, ansiedad, depresión, dolor, jaqueca, enfermedad de Alzheimer, esclerosis múltiple, edema, rinitis alérgica, enfermedad de Crohn, dano ocular, enfermedades inflamatorias oculares, psicosis, enfermedad del movimiento, vómito inducido, emesis, incontinencia urinaria, trastornos psicoinmunológicos o psicosomáticos, cáncer, síntomas de abstinencia de drogas adictivas de opiáceos o nicotina, dano cerebral traumático o hiperplasia prostática benigna. Medicamentos y procedimiento de obtención de los compuestos
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01118412 | 2001-07-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR034921A1 true AR034921A1 (es) | 2004-03-24 |
Family
ID=8178193
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020102847A AR034921A1 (es) | 2001-07-31 | 2002-07-29 | 2-(3,5-bis-trifluormetil-fenil)-n-[6-(1,1-dioxo-1lambda6-tiomorfolin-4-il)-4-(2-metil o 4-fluor-2-metil substituido)fenil-piridin-3-il]-n-metil-isobutiramida |
Country Status (30)
Country | Link |
---|---|
US (1) | US6849624B2 (es) |
EP (1) | EP1414525B1 (es) |
JP (1) | JP4700908B2 (es) |
KR (1) | KR100577101B1 (es) |
CN (1) | CN1289497C (es) |
AR (1) | AR034921A1 (es) |
AT (1) | ATE430600T1 (es) |
BR (1) | BR0211523A (es) |
CA (1) | CA2452502C (es) |
DE (1) | DE60232246D1 (es) |
EA (1) | EA006238B1 (es) |
EC (1) | ECSP044963A (es) |
ES (1) | ES2324209T3 (es) |
GT (1) | GT200200159A (es) |
HK (1) | HK1069136A1 (es) |
HR (1) | HRP20040039A2 (es) |
HU (1) | HUP0400398A3 (es) |
MA (1) | MA27055A1 (es) |
MX (1) | MXPA04000917A (es) |
MY (1) | MY128464A (es) |
NO (1) | NO20040404L (es) |
NZ (1) | NZ530579A (es) |
PA (1) | PA8551601A1 (es) |
PE (1) | PE20030276A1 (es) |
PL (1) | PL366986A1 (es) |
UA (1) | UA77685C2 (es) |
UY (1) | UY27403A1 (es) |
WO (1) | WO2003011860A2 (es) |
YU (1) | YU2704A (es) |
ZA (1) | ZA200400652B (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2444395C (en) * | 2001-04-23 | 2010-12-21 | F. Hoffmann-La Roche Ag | Use of nk-1 receptor antagonists against benign prostatic hyperplasia |
SE521512C2 (sv) * | 2001-06-25 | 2003-11-11 | Niconovum Ab | Anordning för administrering av en substans till främre delen av en individs munhåla |
ES2708552T3 (es) | 2002-12-20 | 2019-04-10 | Niconovum Ab | Método para la preparación de un material particulado que contiene nicotina con una celulosa cristalina (en particular MCC) |
DE602004007486T2 (de) * | 2003-01-31 | 2008-04-30 | F. Hoffmann-La Roche Ag | Neue kristallmodifikation von 2-(3,5-bis-trifluormethyl-phenyl)-n-6-(1,1-dioxo-1lamda-6-thiomorpholin-4-yl)-4(4-fluor-2-methyl-phenyl)-pyridin-3-yl-n-methyl-isobutyramid |
CA2572645C (en) | 2004-07-06 | 2011-01-18 | F. Hoffmann-La Roche Ag | Process for preparing carboxamide derivatives used as intermediates in the synthesis of nk-1 receptor antagonists |
MX2007010034A (es) * | 2005-02-22 | 2007-10-04 | Hoffmann La Roche | Antagonista de nk1. |
CA2598762A1 (en) | 2005-02-25 | 2006-08-31 | F. Hoffmann-La Roche Ag | Tablets with improved drug substance dispersibility |
AU2007224584A1 (en) | 2006-03-16 | 2007-09-20 | Niconovum Ab | Improved snuff composition |
GB0808747D0 (en) | 2008-05-14 | 2008-06-18 | Glaxo Wellcome Mfg Pte Ltd | Novel compounds |
US10383894B2 (en) * | 2010-03-17 | 2019-08-20 | Lutran Industries, Inc. | Human medicinal treatment using salt of peroxymonosulfuric acid |
EP3067349B1 (en) | 2013-11-08 | 2018-02-28 | Kissei Pharmaceutical Co., Ltd. | Carboxymethyl piperidine derivative |
TWI649307B (zh) | 2014-05-07 | 2019-02-01 | 日商橘生藥品工業股份有限公司 | Cyclohexylpyridine derivative |
RU2770050C2 (ru) | 2015-03-04 | 2022-04-14 | Ванда Фармасьютиклз Инк. | Способ лечения с применением традипитанта |
JP7410137B2 (ja) * | 2018-06-08 | 2024-01-09 | バンダ・ファーマシューティカルズ・インコーポレイテッド | トラジピタントを用いる処置方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6435115A (en) * | 1987-07-31 | 1989-02-06 | Nippon Seiko Kk | Bearing device |
IL111960A (en) | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
PL181214B1 (pl) | 1993-12-29 | 2001-06-29 | Merck Sharp & Dohme | Podstawione związki morfolinowe, sposób ich wytwarzania oraz zawierające je kompozycje farmaceutyczne |
TW385308B (en) | 1994-03-04 | 2000-03-21 | Merck & Co Inc | Prodrugs of morpholine tachykinin receptor antagonists |
US5972938A (en) | 1997-12-01 | 1999-10-26 | Merck & Co., Inc. | Method for treating or preventing psychoimmunological disorders |
ATE277905T1 (de) * | 1999-02-24 | 2004-10-15 | Hoffmann La Roche | 4-phenylpyridinderivate und deren verwendung als nk-1 rezeptorantagonisten |
CA2444395C (en) * | 2001-04-23 | 2010-12-21 | F. Hoffmann-La Roche Ag | Use of nk-1 receptor antagonists against benign prostatic hyperplasia |
-
2002
- 2002-07-17 US US10/196,795 patent/US6849624B2/en not_active Expired - Fee Related
- 2002-07-25 PE PE2002000667A patent/PE20030276A1/es not_active Application Discontinuation
- 2002-07-26 NZ NZ530579A patent/NZ530579A/en unknown
- 2002-07-26 MX MXPA04000917A patent/MXPA04000917A/es active IP Right Grant
- 2002-07-26 EP EP02791471A patent/EP1414525B1/en not_active Expired - Lifetime
- 2002-07-26 KR KR1020047001322A patent/KR100577101B1/ko not_active IP Right Cessation
- 2002-07-26 PL PL02366986A patent/PL366986A1/xx not_active Application Discontinuation
- 2002-07-26 JP JP2003517052A patent/JP4700908B2/ja not_active Expired - Fee Related
- 2002-07-26 EA EA200400109A patent/EA006238B1/ru not_active IP Right Cessation
- 2002-07-26 CN CNB028151100A patent/CN1289497C/zh not_active Expired - Fee Related
- 2002-07-26 BR BR0211523-9A patent/BR0211523A/pt not_active Application Discontinuation
- 2002-07-26 WO PCT/EP2002/008311 patent/WO2003011860A2/en active IP Right Grant
- 2002-07-26 YU YU2704A patent/YU2704A/sh unknown
- 2002-07-26 HU HU0400398A patent/HUP0400398A3/hu unknown
- 2002-07-26 UA UA2004021462A patent/UA77685C2/uk unknown
- 2002-07-26 ES ES02791471T patent/ES2324209T3/es not_active Expired - Lifetime
- 2002-07-26 DE DE60232246T patent/DE60232246D1/de not_active Expired - Lifetime
- 2002-07-26 PA PA20028551601A patent/PA8551601A1/es unknown
- 2002-07-26 CA CA2452502A patent/CA2452502C/en not_active Expired - Fee Related
- 2002-07-26 AT AT02791471T patent/ATE430600T1/de active
- 2002-07-29 AR ARP020102847A patent/AR034921A1/es not_active Application Discontinuation
- 2002-07-29 MY MYPI20022848A patent/MY128464A/en unknown
- 2002-07-30 UY UY27403A patent/UY27403A1/es not_active Application Discontinuation
- 2002-07-31 GT GT200200159A patent/GT200200159A/es unknown
-
2004
- 2004-01-15 HR HR20040039A patent/HRP20040039A2/hr not_active Application Discontinuation
- 2004-01-27 ZA ZA200400652A patent/ZA200400652B/xx unknown
- 2004-01-29 NO NO20040404A patent/NO20040404L/no unknown
- 2004-01-29 EC EC2004004963A patent/ECSP044963A/es unknown
- 2004-01-30 MA MA27507A patent/MA27055A1/fr unknown
-
2005
- 2005-02-28 HK HK05101662A patent/HK1069136A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR034921A1 (es) | 2-(3,5-bis-trifluormetil-fenil)-n-[6-(1,1-dioxo-1lambda6-tiomorfolin-4-il)-4-(2-metil o 4-fluor-2-metil substituido)fenil-piridin-3-il]-n-metil-isobutiramida | |
WO2007038209A3 (en) | Fused tetracyclic mglur1 antagonists as therapeutic agents | |
ES2139754T3 (es) | 3-fenil-2-isoxazolinas como agentes antiinflamatorios. | |
DE69332762T2 (de) | Cathecoldiether als selektive pde iv hemmungsmittel | |
TW200609231A (en) | Mglur1 antagonists as therapeutic agents | |
BR0313122A (pt) | Antranilamidopiridinas inibidoras de vegfr-2 e vegfr-3 | |
ATE530544T1 (de) | Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren | |
CY1105140T1 (el) | Παραγωγα κυανοανθρανυλαμιδιου και η χρηση τους ως φαρμακευτικα μεσα | |
MX2007000046A (es) | Compuestos, composiciones y metodos de imidazolo relacionados para su uso. | |
MX2008002366A (es) | Antagonistas triciclicos fusionados de mglur1 como agentes terapeuticos. | |
DK1593387T3 (da) | Sammensætninger for behandling af uhæmmede interpersonelle og adfærdsmæssige forstyrrelser | |
BRPI0005616B8 (pt) | 2-(3,5-bis-trifluormetil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-tolil-piridin-3-il)-isobutiramida, seu processo de preparação e seu uso, bem como medicamento | |
JP2005500354A5 (es) | ||
IL158704A0 (en) | 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | |
MXPA03011702A (es) | Composicion que comprende un inhibidor de fosodiesterasa 4 y un antagonista de receptor h1 y el uso de los mismos para la elaboracion de un medicamento para el tratamiento de enfermedades respiratorias. | |
UY25824A1 (es) | Antagonista del receptor de vitronectina | |
CO4480025A1 (es) | Nuevos usos de ciertos derivados del indol en el tratamiento o profilaxis de trastornos medicos | |
HUP0300934A2 (hu) | Gyulladásos betegségek kezelése | |
IL158695A0 (en) | 4-(phenyl-piperidin-4-yldine-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | |
CA2514037A1 (en) | Crystalline modification of 2-(3,5-bis-trifluoromethyl-phenyl)-n-[6-(1,1-dioxo-1.lambda.6-thiomorpholin-4-yl)-4(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-n-methyl-isobutyramide | |
ATE294780T1 (de) | Arylpiperidin- und aryl-1,2,5,6- tetrahydropyridinamid-derivate mit 5ht1a rezeptor aktivität | |
WO2002076437A3 (en) | Methods for treating neurodegenerative diseases including alzheimer's | |
EA200702534A1 (ru) | Применение бензоильного производного 3-аминокарбазола для лечения расстройства, связанного с продукцией простагландина e2(pge2) | |
ATE441633T1 (de) | Nk1-antagonisten | |
ES2176687T3 (es) | Nuevas n-metil-n-(4-(4-(1h-benzimidazol-2-il-amino)piperidin-1-il)-2-(aril)butil)benzamidas sustituidas utiles para el tratamiento de enfermedades alergicas. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |